Recent Updates
Recently added Catalysts
JAZZ Neutral Sentiment

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: Cowen 43rd...

Key Takeaway: Jazz Pharmaceuticals plc has announced its participation in several upcoming investor conferences, including the Cowen 43rd Annual Health Care Conference and the J.P. Morgan 12th Annual Napa Valley Biotech Forum. These events provide the company with an opportunity to connect with investors and discuss their diverse portfolio and commitment to developing life-changing medicines. Jazz Pharmaceuticals focuses on therapeutic areas like neuroscience and oncology, aiming to provide novel treatment options for patients worldwide.
Price reaction · baseline $143.85 (2023-02-24 close) · 1 other JAZZ headline(s) in the window, move may be shared
day 0 close · peak
-1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in prominent investor conferences showcases company visibility.
  • Potential for engaging with investors about their innovative biopharma developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2

Full Press Release Details

DUBLIN , Feb. 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the following upcoming investor conferences:
Cowen 43rd Annual Health Care Conference
J.P. Morgan 12 th Annual Napa Valley Biotech Forum
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717

Frequently Asked Questions

What conferences will Jazz Pharmaceuticals attend?

Jazz Pharmaceuticals will participate in the Cowen 43rd Annual Health Care Conference and the J.P. Morgan 12th Annual Napa Valley Biotech Forum.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

What areas does Jazz Pharmaceuticals focus on?

The company focuses on neuroscience and oncology, developing innovative medicines.

How many countries does Jazz Pharmaceuticals serve?

Jazz Pharmaceuticals serves patients in nearly 75 countries worldwide.

Who should I contact for investor relations?

For investor relations, contact Andrea N. Flynn, Ph.D. at Jazz Pharmaceuticals.

Last updated: Feb 27, 2023